Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288858 · ClinicalTrials.gov registry record · NA
To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair
A NA study of Hair Thinning, sponsored by Irish Response t/a Lifes2good.
- Completed
- Registry status
- NA
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT02288858: Completed NA study of Hair Thinning, sponsored by Irish Response t/a Lifes2good.
NCT02288858 is a NA study of Hair Thinning that has completed, run by Irish Response t/a Lifes2good. The registered enrollment target is 96 participants, above the 56-participant average among 10 other Hair Thinning trials with a reported enrollment target (71% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02288858, a NA study of Hair Thinning, has completed, sponsored by Irish Response t/a Lifes2good.
- COMPLETED
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this multi-site, double-blind, placebo-controlled clinical study, conducted for Lifes2Good, is to evaluate certain physiological effects of Viviscal Oral Supplement compared to a placebo in female subjects with self-perceived thinning hair associated with poor diet, stress, hormonal influences, or abnormal menstrual cycles. Viviscal is an oral food supplement specifically designed to promote the quality of existing hair growth and/or to promote new hair re-growth for women suffering from temporary thinning hair. It does not contain hormones, drugs, or industry by-products. Viviscal has been marketed in Europe for over 15 years. The key ingredient is AminoMar C - a protein rich compound of marine extracts blended with soluble silica and fortified with Vitamin C. Viviscal provides essential nutrients to nourish hair naturally from within. Viviscal works over several months of use to improve the appearance of thinning hair.
Primary Outcome
The numbers of scalp hairs shed at month 3 and month 6 when compared with baseline values.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Viviscal Oral Supplement Tablets
Study Locations (1)
Texas
- Stephens Associates Inc. - Richardson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-11 |
| Phase | NA |
What the finished NCT02288858 record still lists
NCT02288858 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, above the 56-participant average among 10 other Hair Thinning trials with a reported enrollment target (71% higher).
The record links to 1 condition, with Hair Thinning appearing as the primary indexed condition, and to 1 intervention - of which Viviscal Oral Supplement Tablets is the first listed.
NCT02288858 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02288858 about?
NCT02288858 is a clinical study titled "To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair". The purpose of this multi-site, double-blind, placebo-controlled clinical study, conducted for Lifes2Good, is to evaluate certain physiological effects of Viviscal Oral Supplement compared to a placebo in female subjects with self-perceived thinning hair associated with poor diet, stress, hormonal i...
What is the current status of trial NCT02288858?
This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2011-04. Estimated completion is 2011-11.
What conditions does trial NCT02288858 study?
This clinical trial studies the following conditions: Hair Thinning.
What interventions are being tested in trial NCT02288858?
The interventions under investigation include: Viviscal Oral Supplement Tablets (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02288858?
This trial is sponsored by Irish Response t/a Lifes2good, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02288858 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hair Thinning
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02288858's enrollment target sits among peer trials
96 3rd of 10 higher than 8 of 10 other Hair Thinning trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hair Thinning trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair
RECRUITING · NA
-
A Clinical Trial to Examine the Efficacy of a Dietary Supplement to Improve the Health and Appearance of Hair.
ACTIVE NOT RECRUITING · NA
-
A Clinical Trial to Examine the Efficacy of a Supplement to Support Healthy Hair and Skin
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning
ACTIVE NOT RECRUITING · NA
-
The Effects of an Oral Hair Supplement on Hair Density, Growth, and Microbiome
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia